이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Marksans Pharma 과거 수익 실적
과거 기준 확인 3/6
Marksans Pharma은 연평균 22.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 17%였습니다. 매출은 연평균 15.7%의 비율로 증가했습니다. Marksans Pharma의 자기자본이익률은 15.1%이고 순이익률은 14.4%입니다.
주요 정보
22.4%
수익 성장률
20.9%
EPS 성장률
Pharmaceuticals 산업 성장 | 17.5% |
매출 성장률 | 15.7% |
자기자본 수익률 | 15.1% |
순이익 | 14.4% |
최근 수익 업데이트 | 31 Mar 2024 |
최근 과거 실적 업데이트
Recent updates
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08수익 및 비용 분석
수익 및 비용 분석
Marksans Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
31 Mar 24 | 21,774 | 3,137 | 2,936 | 0 |
31 Dec 23 | 21,034 | 3,164 | 2,875 | 0 |
30 Sep 23 | 19,971 | 2,965 | 2,752 | 0 |
30 Jun 23 | 19,184 | 2,743 | 2,637 | 0 |
31 Mar 23 | 18,521 | 2,653 | 2,521 | 0 |
31 Dec 22 | 17,842 | 2,123 | 2,436 | 0 |
30 Sep 22 | 16,670 | 2,004 | 2,375 | 0 |
30 Jun 22 | 15,756 | 1,847 | 2,326 | 0 |
31 Mar 22 | 14,908 | 1,868 | 2,250 | 0 |
31 Dec 21 | 14,069 | 2,367 | 2,351 | 0 |
30 Sep 21 | 14,026 | 2,473 | 2,269 | 0 |
30 Jun 21 | 14,064 | 2,518 | 2,037 | 0 |
31 Mar 21 | 13,762 | 2,385 | 2,096 | 0 |
31 Dec 20 | 13,817 | 2,018 | 1,908 | 0 |
30 Sep 20 | 13,142 | 1,724 | 1,833 | 0 |
30 Jun 20 | 12,203 | 1,476 | 1,700 | 0 |
31 Mar 20 | 11,344 | 1,208 | 1,785 | 0 |
31 Dec 19 | 10,463 | 879 | 1,719 | 0 |
30 Sep 19 | 9,972 | 834 | 1,677 | 0 |
30 Jun 19 | 10,099 | 780 | 1,631 | 0 |
31 Mar 19 | 10,001 | 804 | 1,659 | 0 |
31 Dec 18 | 9,523 | 666 | 1,601 | 0 |
30 Sep 18 | 9,223 | 582 | 1,599 | 0 |
30 Jun 18 | 9,272 | 463 | 1,474 | 0 |
31 Mar 18 | 9,127 | 358 | 1,534 | 0 |
31 Dec 17 | 8,918 | 343 | 1,528 | 0 |
30 Sep 17 | 8,949 | 275 | 1,550 | 0 |
30 Jun 17 | 8,015 | 187 | 1,492 | 0 |
31 Mar 17 | 7,672 | 113 | 1,547 | 0 |
31 Dec 16 | 7,926 | 70 | 1,475 | 0 |
30 Sep 16 | 7,948 | 136 | 1,458 | 0 |
30 Jun 16 | 8,699 | 481 | 1,424 | 0 |
31 Mar 16 | 8,933 | 785 | 1,270 | 0 |
31 Dec 15 | 8,536 | 1,093 | 1,585 | 0 |
30 Sep 15 | 8,495 | 1,191 | 1,397 | 0 |
30 Jun 15 | 8,045 | 1,154 | 728 | 0 |
31 Mar 15 | 7,967 | 1,094 | 758 | 0 |
31 Dec 14 | 7,850 | 950 | 1,482 | 0 |
30 Sep 14 | 7,405 | 897 | 1,121 | 0 |
30 Jun 14 | 6,914 | 786 | 693 | 0 |
31 Mar 14 | 6,300 | 719 | 1,091 | 0 |
31 Dec 13 | 5,950 | 1,020 | 1,013 | 0 |
30 Sep 13 | 5,406 | 877 | 994 | 0 |
30 Jun 13 | 4,848 | 817 | 588 | 0 |
양질의 수익: MARKSANS 의 비현금 수입 수준이 높습니다.
이익 마진 증가: MARKSANS 의 현재 순이익 이익률 (14.4%) 작년보다 높습니다 (14.3%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: MARKSANS 의 수익은 지난 5년 동안 매년 22.4% 씩 크게 증가했습니다.
성장 가속화: 지난 1년간 MARKSANS 의 수익 증가율( 18.2% )은 5년 평균( 22.4% 보다 낮습니다. 년도).
수익 대 산업: 지난 1년간 MARKSANS 수익 증가율( 18.2% )은 Pharmaceuticals 업계 18% 초과했습니다.
자기자본 수익률
높은 ROE: MARKSANS 의 자본 수익률( 15.1% )은 낮음으로 간주됩니다.